Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC) Meeting Abstract


Authors: Necchi, A.; Nishiyama, H.; Matsubara, N.; Lee, J. L.; Petrylak, D. P.; De Wit, R.; Drakaki, A.; Liepa, A. M.; Zimmermann, A.; Bell-McGuinn, K. M.; Powles, T.
Abstract Title: Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC)
Meeting Title: 2018 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 6 Suppl.
Meeting Dates: 2018 Feb 8-10
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-20
Language: English
ACCESSION: WOS:000436179500413
DOI: 10.1200/JCO.2018.36.6_suppl.419
PROVIDER: wos
Notes: Meeting Abstract: 419 -- Source: Wos
Altmetric Score
MSK Authors